Significantly, PFKFB3/iPFK2 is involved in the effect of rosiglitazone, one of the only two currently prescribed medicines as insulin-sensitizers for the treatment of type 2 diabetes, on suppressing intestinal inflammation. This evidence concerns the gene PFKFB3 and type 2 diabetes mellitus.